Medpace Holdings, Inc. $MEDP Shares Bought by Candriam S.C.A.

Candriam S.C.A. lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 164.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 103,349 shares of the company’s stock after purchasing an additional 64,314 shares during the quarter. Candriam S.C.A.’s holdings in Medpace were worth $49,627,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of MEDP. AQR Capital Management LLC grew its position in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after buying an additional 183,645 shares in the last quarter. Norges Bank acquired a new stake in shares of Medpace in the 4th quarter worth approximately $102,156,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Medpace by 92.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after acquiring an additional 166,654 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 0.5%

Shares of Medpace stock opened at $538.23 on Friday. The stock has a market cap of $15.37 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 2.72 and a beta of 1.15. The business has a fifty day simple moving average of $467.24 and a 200-day simple moving average of $496.03. Medpace Holdings, Inc. has a 12 month low of $306.70 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on MEDP. BMO Capital Markets lowered their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and increased their price target for the company from $490.00 to $515.00 in a research note on Tuesday. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $547.00 price objective (up from $477.00) on shares of Medpace in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $469.17.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 20.50% of the stock is currently owned by company insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.